News and Insights

What's New

A 'Pink Tax' in Oncology

Evolent program flags low-value regimen years ahead of failed clinical trial

Long before recent trial results showed that a lung cancer treatment had no survival advantage, Evolent was following the early evidence and working with providers to avoid it.

Improving primary care physician and specialist coordination and engagement

Aligning oncology incentives to drive high-value cancer care

A Health Care Transformation Task Force case study highlights Evolent's model for managing the quality and affordability of oncology drugs.

Read Case Study

Optimizing radiation in head and neck cancer

Optimizing radiation in head and neck cancer: Minimizing adverse effects

Senior Medical Director Dr. Amin Mirhadi writes in Evidence-Based Oncology about approaches to extend survival while preserving critical organs and quality of life.

Grappling with cancer’s time toxicity challenge

Grappling with cancer’s time toxicity challenge

How much time do cancer patients spend in healthcare settings, and how can we decrease it?

Get to know Chief Clinical Officer Dr. David Lim

Q&A: Dr. David Lim on the future of value-based specialty care

Our chief clinical officer discusses his unlikely path to the field and where he thinks it's headed.

Grading accelerated approval oncology drugs

Grading accelerated approval oncology drugs

Evolent oncology experts have devised a novel metric to help guide decisions about which regimens to include on clinical pathways.

Evolent and American Oncology Network

Evolent and American Oncology Network unveil innovative model to improve cancer care

Evolent’s partnership with one of the nation’s fastest growing community oncology networks aims to enable top-quality, more affordable, and connected cancer care.

Read Press Release

Comprehensive Cancer Care Navigation- Improving Patient Outcomes

Comprehensive Cancer Care Navigation: Improving Patient Outcomes

Dr. Kamal Golla speaks with the Empowered Patient Podcast about the history and future of cancer care navigation.

Listen to Podcast

What's driving oncology drug spend

What’s driving oncology drug spend?

To better manage oncology drug spending, first consider the factors pushing it ever higher.

Supercharging Care Navigation

Supercharging care navigation

The combination of patient engagement and clinical decision support can unlock value across the cancer journey.

Navigating risk, treatment and reimbursement in precision oncology

Navigating risk, treatment and reimbursement in precision oncology

Dr. Sadie Dobrozsi joins Managed Care Cast to discuss the state of predictive genomics in cancer care.

Listen to Podcast

Scientific Investment in Precision Oncology

Scientific investment in precision oncology

Dr. Sadie Dobrozsi joins the Oncology Overdrive podcast to discuss issues in genomics testing, from its role in treatment planning to ethical concerns.

Advances in Ovarian Cancer- Using Genomics and Optimizing Maintenance Therapy

Advances in ovarian cancer: Using genomics and optimizing maintenance therapy

Writing in Evidence-Based Oncology, oncology pharmacist Amy VanGalder explores how genomic profiling is enabling clinicians to tailor therapies with greater precision.

The importance of patient selection for immunotherapy drugs

Q&A: The importance of patient selection for immunotherapy drugs

Dr. Andrew Hertler speaks with Urban Health Today about the need to identify patients most likely to benefit from PD-L1 inhibitors.

Too Many Ovarian Cancer Patients Missing Out on Life-Changing Genetic Testing

Too many ovarian cancer patients are missing out on life-changing genetic testing

Dr. Sadie Dobrozsi talks with Patient Power about overcoming the barriers to testing.

Q&A- Cardiotoxicity among cancer patients

Q&A: Cardiotoxicity among cancer patients

Oncology pharmacist Terra Wonsettler speaks with Urban Health Today about a serious side effect of certain cancer treatments – damage to the heart.

Evolent program achieves 20% reduction in use of low-value oncology regimens

Evolent program achieves 20% reduction in use of low-value oncology regimens

Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain.

Read Press Release

Clinical trials must represent those who will receive therapy

Clinical trials must represent those who will receive therapy

Real-world patients often experience worse outcomes than those seen in clinical trials. Lack of representation may be one reason, writes Dr. Andrew Hertler.